首页 | 本学科首页   官方微博 | 高级检索  
     


The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors
Authors:Dennis M Timmerman  Thomas F Eleveld  Ad J M Gillis  Carlijn C Friedrichs  Sanne Hillenius  Tessa L Remmers  Sruthi Sriram  Leendert H J Looijenga
Affiliation:Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands; (D.M.T.); (T.F.E.); (A.J.M.G.); (C.C.F.); (S.H.); (T.L.R.); (S.S.)
Abstract:Germ cell tumors (GCTs) are considered to be highly curable; however, there are major differences in the outcomes related to histology and anatomical localization. GCTs originating from the testis are, overall, sensitive to platinum-based chemotherapy, whereas GCTs originating from the mediastinum show a worse response, which remains largely unexplained. Here, we address the differences among GCTs from two different anatomical locations (testicular versus mediastinal/extragonadal), with a specific focus on the role of the P53 pathway. It was recently shown that GCTs with TP53 mutations most often localize to the mediastinum. To elucidate the underlying mechanism, TP53 knock-out lines were generated in cisplatin-sensitive and -resistant clones of the representative 2102Ep cell line (wild-type TP53 testicular GCT) and NCCIT cell line (hemizygously mutated TP53, mutant TP53 mediastinal GCT). The full knock-out of TP53 in 2102Ep and resistant NCCIT resulted in an increase in cisplatin resistance, suggesting a contributing role for P53, even in NCCIT, in which P53 had been reported to be non-functional. In conclusion, these results suggest that TP53 mutations contribute to the cisplatin-resistant phenotype of mediastinal GCTs and, therefore, are a potential candidate for targeted treatment. This knowledge provides a novel model system to elucidate the underlying mechanism of clinical behavior and possible alternative treatment of the TP53 mutant and mediastinal GCTs.
Keywords:human malignant germ cell tumors  mediastinal germ cell tumors  testicular germ cell tumors  cisplatin resistance  TP53  NCCIT  2102Ep  stratification
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号